Physician profile
Carly Geier
NPI 1922761774
$9,619.07
in general payments reported to CMS, 2019-2025
24 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 99% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $1,619 · 2023: $2,650 · 2024: $2,465 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,687 · Education: $13.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,687.27 |
| Education | $13.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,617.85 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,223.92 | 2021-2025 | Caplyta |
| Alkermes, INC. | $903.69 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $756.29 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $632.60 | 2022-2025 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $618.56 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $523.75 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $462.30 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $424.92 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $405.46 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $383.86 | 2023-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $315.55 | 2023-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $271.10 | 2022-2023 | Jornay Pm |
| Almatica Pharma LLC | $181.68 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Tempus Ai, INC | $173.62 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $162.99 | 2022-2025 | Trintellix |
| Noven Therapeutics, LLC | $142.66 | 2024-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $128.30 | 2025 | Jornay Pm |
| Tris Pharma INC | $112.07 | 2025 | Dyanavel Xr, Quillichew Er |
| E.R. Squibb & Sons, L.L.C. | $63.92 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $49.64 | 2023-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $25.89 | 2021 | |
| Indivior INC. | $19.63 | 2023 | Perseris |
| Jazz Pharmaceuticals INC. | $18.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Geier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.